One of the many things I heard at AUTM was the need for Universities to find alternative funding sources now that the NIH budget was drying up. Many of those people took time to find me and pass me their card in the thought that I might be that source.
Given my last post on the matter, which is actually your problem to begin with, you have to realize that the sales of research reagents will fall. Since they will fall, I will have less money to spend. A nasty little link where your problem becomes my problem, which means I can't solve your problem.
Given the diagnostic side of things, where I am also active, there is money there. BUT there are many many many fewer things that I license for diagnostics vs. our research business. There are just more research tools and they are easier to launch in to the market. Diagnostics have long lead times and large amounts of cash needed per launch. Research tools are easy.
SO - the diagnostic business has money in it, but for very few projects. Research tools has no money, but needs lots of projects.
next couple of years should be interesting.